Margaret Cuomo
Family · New York, NYNPI 1376010322
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by AstraZeneca at 53.0% of the total. Reporting peaked in 2024 at $11,871 and has fallen 51.0% since, to $5,812 in 2025. Among family clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 159 payments — averaging $132.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$11K
- Alnylam Pharmaceuticals Inc.$6K
- Bridgebio Pharma, Inc.$985
- Abbott$789
- Novartis$766
- Kiniksa Pharmaceuticals International, PLC$122
- plus $740 from 16 others
What the payments were for
- Consulting fees$3,85118%
- Speaking & faculty fees$12,04457%
- Travel & lodging$9665%
- Food & beverage$4,18920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 35 | $11,164 |
| Alnylam Pharmaceuticals Inc. | 23 | $6,484 |
| Bridgebio Pharma, Inc. | 3 | $985 |
| Abbott | 6 | $789 |
| Novartis | 51 | $766 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $122 |
| Daiichi Sankyo Inc. | 5 | $117 |
| Merck | 5 | $105 |
| Boehringer Ingelheim | 5 | $82 |
| Amgen | 4 | $69 |
| Cvrx, Inc. | 2 | $55 |
| Kestra Medical Technology Services, Inc. | 1 | $53 |
| Scpharmaceuticals Inc. | 3 | $51 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $45 |
| Lexicon Pharmaceuticals, Inc. | 2 | $32 |
| Amarin Pharma, Inc. | 1 | $22 |
| United Therapeutics Corporation | 1 | $21 |
| Novo Nordisk | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Bayer | 1 | $18 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WAINUA$7,269
- AMVUTTRA$5,929
- Attruby$985
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$555
- CARDIOMEMS$159
How this compares
$21,049 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 892 | $27,200,224 |
| VyndaqelTafamidis Meglumine | 22 | $692,050 |
| WainuaEplontersen Sodium | 11 | $473,823 |
| EliquisApixaban | 236 | $311,636 |
| JardianceEmpagliflozin | 142 | $218,817 |
| FarxigaDapagliflozin Propanediol | 148 | $199,880 |
| EntrestoSacubitril/Valsartan | 95 | $152,174 |
| CamzyosMavacamten | 16 | $119,486 |
| XareltoRivaroxaban | 43 | $50,715 |
| MounjaroTirzepatide | 17 | $17,006 |
| OzempicSemaglutide | 11 | $10,154 |
| Eplerenone | 105 | $8,406 |
| Torsemide | 153 | $3,788 |
| Sildenafil Citrate | 12 | $3,554 |
| Spironolactone | 232 | $2,157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $12 | $28,203,9091,150 claims |
| AstraZenecaWainua, Farxiga | $11,164 | $673,702159 claims |
| Boehringer IngelheimJardiance | $82 | $218,817142 claims |
| NovartisEntresto | $766 | $152,17495 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $19 | $119,48616 claims |
| Johnson & JohnsonXarelto | $18 | $50,71543 claims |
| Novo NordiskOzempic | $20 | $10,15411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.
Other family in New York
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Mary Sullivan-WhalenNew York$137K
- Leslie WoronaNew York$77K
- Thomas SaglimbeniNew York$48K
- Kathryn JohnsonNew York$48K
- Derek PinedaNew York$38K
- Rebecca SchoriNew York$32K
- Evangelia NezisNew York$22K
- Colette NelsonNew York$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.